Table 2– Treatment outcomes of 98 multidrug-resistant tuberculosis (TB) cases enrolled in two specialised clinical centres in Italy and the Netherlands after 30, 60 and 90 days of treatment
VariablesTotalItalian cohort: cases#Dutch cohort: controlsp-value
Sputum-smear conversion
 At 30 days of treatment16/50 (32.0)7/32 (21.9)9/18 (50.0)0.04
 At 60 days of treatment27/48 (56.3)20/32 (62.5)7/16 (43.8)0.22
 At 90 days of treatment37/48 (77.1)28/32 (87.5)9/16 (56.3)0.02
Sputum-culture conversion
 At 30 days of treatment24/66 (36.4)12/37 (32.4)12/29 (41.4)0.45
 At 60 days of treatment37/62 (59.7)24/37 (64.9)13/25 (52.0)0.31
 At 90 days of treatment46/61 (75.4)31/37 (83.8)15/24 (62.5)0.06
Days from start of anti-TB therapy to sputum smear conversion51 (28.0–75.0)52.5 (38.5–65.0)46.0 (6.0–157.0)0.85
Days from start of anti-TB therapy to culture conversion42 (16.5–82.0)42.0 (28.0–65.0)46.0 (13.0–96.0)0.96
  • Data are presented as n/N (%) or median (interquartile range), unless otherwise stated. #: meropenem–clavulanate containing anti-TB regimen; : meropenem–clavulanate-sparing anti-TB regimen.